by support | Nov 28, 2022 | Uncategorized
The voice of the patient has a role in the drug development and approval process. In fact, recent legislation mandates an increased emphasis on incorporating the patient perspective into the drug approval process.
by support | Nov 28, 2022 | Uncategorized
The FDA workshop on “The Development of Antibiotics for the Treatment of NTM Disease” on April 8, 2019 was very successful, with more than 100 people attending in person. The agenda focused on issues surrounding clinical trials and the development of a validated...
by support | Nov 28, 2022 | Uncategorized
Dear Friends of NTM Info & Research, It is with a mixture of gratitude and sadness that I announce the retirement of Philip Leitman as President of NTM Info & Research. Philip, who co-founded NTMir with his late wife, Fern, will continue as President Emeritus...
by support | Nov 28, 2022 | Uncategorized
NTM Info & Research (NTMir), the national nonprofit organization advocating on behalf of patients with nontuberculous mycobacterial (NTM) lung disease, applauds the European Commission’s decision to grant marketing authorization for ARIKAYCE® Liposomal 590 mg...
by support | Nov 28, 2022 | Uncategorized
At the American Thoracic Society International Conference in May, Amy Leitman from NTM Info & Research, along with Dr. Mehdi Mirsaeidi from the University of Miami, presented the results of a survey on geographic diversity of nontuberculous mycobacteria species...
by support | Nov 28, 2022 | Uncategorized
NTM Info & Research Awards Grant to Oregon Health & Science University Study Will Assess Efficacy of Hypertonic Saline in Treatment of Pulmonary NTM Disease CORAL GABLES, FL, November 24, 2020 – NTM Info & Research (NTMir), the national nonprofit...
